Targeted therapies with immunotherapies in kidney cancer

The following video is an interview with Professor Thomas Powles from Barts Cancer Centre in London, where he is Professor of Genitourinary Oncology.

During the interview, Professor Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium.  The data from KETNOTE-426 potentially redefines the standard of care in treating advanced kidney cancer. The takeaway message from this study is that the pembrolizumab/axitinib combination improves progression-free survival and overall survival versus sunitinib in advanced kidney cancer.

View the video on UroToday here

Share this Post!


Related post

  TOP